Breaking News

Tweet TWEET

Echo Therapeutics Announces Closing of Public Offering of Common Stock

    Echo Therapeutics Announces Closing of Public Offering of Common Stock

PR Newswire

PHILADELPHIA, Dec. 27, 2012

PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced the closing of a previously announced underwritten public
offering of 3,200,000 shares of its common stock and the fully exercised
over-allotment option to purchase 480,000 additional shares, offered at a
price of $0.95 per share. The gross proceeds to Echo from this offering were
approximately $3.5 million, before deducting the underwriting discount and
other offering expenses payable by Echo.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Aegis Capital Corp. acted as the sole book-running manager for the offering.

Feltl and Company acted as co-manager for the offering.

The offering is being made pursuant to a shelf registration statement that
Echo previously filed with the Securities and Exchange Commission (the "SEC")
and which is effective. A final prospectus supplement and accompanying base
prospectus has been filed with SEC and is available on the SEC's website at
www.sec.gov. Electronic copies of the final prospectus supplement and
accompanying base prospectus relating to the offering may also be obtained by
contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue,
18^th Floor, New York, NY, 10019, telephone: 212-813-1010 or email:
prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements, including statements regarding Echo's
proposed public offering. These statements are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to general market conditions and the other risks and
uncertainties identified and described in more detail in Echo's filings with
the Securities and Exchange Commission. Echo undertakes no obligation to
publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx







SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com